A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
Saved in:
| Title: | A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. |
|---|---|
| Authors: | DePalo DK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Dugan MM; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Naqvi SMH; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Ollila DW; University of North Carolina, Chapel Hill, North Carolina, USA., Hieken TJ; Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA., Block MS; Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA., van Houdt WJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Wouters MWJM; Netherlands Cancer Institute, Amsterdam, Netherlands., Reijers SJM; Netherlands Cancer Institute, Amsterdam, Netherlands., Asher N; Skin Cancer and Melanoma Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel., Broman KK; University of Alabama at Birmingham, Birmingham, Alabama, USA.; United States Department of Veterans Affairs, Birmingham VA Medical Center, Birmingham, Alabama, USA., Duncan Z; University of Alabama at Birmingham, Birmingham, Alabama, USA., Anderson M; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Gyorki DE; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Snow H; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Held J; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Farma JM; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Vetto JT; Oregon Health and Science University, Portland, Oregon, USA., Hui JYC; University of Minnesota, Minneapolis, Minnesota, USA., Kolbow M; University of Minnesota, Minneapolis, Minnesota, USA., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Kim Y; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Karapetyan L; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Ny L; Sahlgrenska University Hospital, Gothenburg, Sweden.; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., van Akkooi ACJ; Netherlands Cancer Institute, Amsterdam, Netherlands.; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Olofsson Bagge R; Sahlgrenska University Hospital, Gothenburg, Sweden.; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Zager JS; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA. |
| Source: | Cancer [Cancer] 2025 Jan 01; Vol. 131 (1), pp. e35636. Date of Electronic Publication: 2024 Nov 10. |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35636 |
